ClinicalTrials.gov
ClinicalTrials.gov Menu

STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma (STORM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01653067
Recruitment Status : Unknown
Verified October 2016 by Mathias Witzens-Harig, University Hospital Heidelberg.
Recruitment status was:  Active, not recruiting
First Posted : July 30, 2012
Last Update Posted : October 27, 2016
Sponsor:
Collaborators:
Johannes Gutenberg University Mainz
Technische Universität München
Ludwig-Maximilians - University of Munich
University Hospital Ulm
University Hospital Erlangen
Charite University, Berlin, Germany
University Hospital Freiburg
Johann Wolfgang Goethe University Hospital
Information provided by (Responsible Party):
Mathias Witzens-Harig, University Hospital Heidelberg